5T4R
NMR solution structure of the Nav1.7 selective spider venom-derived peptide Pn3a
Summary for 5T4R
| Entry DOI | 10.2210/pdb5t4r/pdb |
| NMR Information | BMRB: 30164 |
| Descriptor | Mu-theraphotoxin-Pn3a (1 entity in total) |
| Functional Keywords | tarantula peptide toxin, inhibitor cystine knot, voltage-gated sodium channel modifier, voltage sensor modifier, toxin |
| Biological source | Theraphosidae (tarantulas) |
| Total number of polymer chains | 1 |
| Total formula weight | 4285.99 |
| Authors | Rosengren, K.J.,Armstrong, D.A.,Vetter, I. (deposition date: 2016-08-30, release date: 2017-09-06, Last modification date: 2024-11-13) |
| Primary citation | Deuis, J.R.,Dekan, Z.,Wingerd, J.S.,Smith, J.J.,Munasinghe, N.R.,Bhola, R.F.,Imlach, W.L.,Herzig, V.,Armstrong, D.A.,Rosengren, K.J.,Bosmans, F.,Waxman, S.G.,Dib-Hajj, S.D.,Escoubas, P.,Minett, M.S.,Christie, M.J.,King, G.F.,Alewood, P.F.,Lewis, R.J.,Wood, J.N.,Vetter, I. Pharmacological characterisation of the highly Na V 1.7 selective spider venom peptide Pn3a. Sci Rep, 7:40883-40883, 2017 Cited by PubMed Abstract: Human genetic studies have implicated the voltage-gated sodium channel Na1.7 as a therapeutic target for the treatment of pain. A novel peptide, μ-theraphotoxin-Pn3a, isolated from venom of the tarantula Pamphobeteus nigricolor, potently inhibits Na1.7 (IC 0.9 nM) with at least 40-1000-fold selectivity over all other Na subtypes. Despite on-target activity in small-diameter dorsal root ganglia, spinal slices, and in a mouse model of pain induced by Na1.7 activation, Pn3a alone displayed no analgesic activity in formalin-, carrageenan- or FCA-induced pain in rodents when administered systemically. A broad lack of analgesic activity was also found for the selective Na1.7 inhibitors PF-04856264 and phlotoxin 1. However, when administered with subtherapeutic doses of opioids or the enkephalinase inhibitor thiorphan, these subtype-selective Na1.7 inhibitors produced profound analgesia. Our results suggest that in these inflammatory models, acute administration of peripherally restricted Na1.7 inhibitors can only produce analgesia when administered in combination with an opioid. PubMed: 28106092DOI: 10.1038/srep40883 PDB entries with the same primary citation |
| Experimental method | SOLUTION NMR |
Structure validation
Download full validation report
